SCHEMBL10366338

SCHEMBL10366338

O=Cc1ccc2c(c1)CCCS2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.45
HPGD P15428 2/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
KMT2A Q03164 1/20 0.45
PTGS2 P35354 2/20 0.34
KDM4E B2RXH2 2/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
HSD17B10 Q99714 1/20 0.34
ALDH1A3 P47895 5/20 0.34
PTGS1 P23219 1/20 0.34
CYP2A6 P11509 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TSHR P16473 1/20 0.32
TRIM24 O15164 1/20 0.32
TRIM33 Q9UPN9 1/20 0.32
ESR1 P03372 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4824838 0.89 ALDH1A1 (0.40) ALDH1A1HPGDMAPTMEN1GAA
SCHEMBL24125026 0.82 ALDH1A1 (0.36) ALDH1A1HPGDMAPTPTGS2PTGS1
SCHEMBL7235884 0.76 ALDH1A1 (0.38) ALDH1A1HPGDMAPTMEN1GAA
SCHEMBL2798056 0.75 ALDH1A1 (0.40) ALDH1A1HPGDPTGS2KDM4ERAB9A
SCHEMBL8244272 0.75 RYR2 (0.55) ALDH1A1HPGDMAPTMEN1GAA
SCHEMBL1525801 0.72 ALDH1A1 (0.53) ALDH1A1HPGDMAPTMEN1GAA
SCHEMBL1525600 0.72 ALDH1A1 (0.53) ALDH1A1HPGDMAPTMEN1GAA
SCHEMBL29942408 0.72 ALDH1A1 (0.53) ALDH1A1HPGDMAPTMEN1GAA
SCHEMBL7512041 0.72 ALDH1A1 (0.53) ALDH1A1HPGDMAPTMEN1GAA
SCHEMBL13392736 0.72 ALDH1A1 (0.35) ALDH1A1HPGDMAPTMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 WO disclosed
EP-2840076-B1 BICYCLIC COMPOUND TOA EIYO LTD (JP) 2017-10-25 EP disclosed
US-9290440-B2 Bicyclic compound TOA EIYO LTD. (JP) 2016-03-22 US disclosed
US-20150119418-A1 BICYCLIC COMPOUND TOA EIYO LTD. (JP) 2015-04-30 US disclosed
EP-2840076-A1 BICYCLIC COMPOUND TOA Eiyo Ltd. (JP) 2015-02-25 EP disclosed
EP-0207605-B1 HYPOGLYCEMIC THIAZOLIDINEDIONES PFIZER INC. (US) 1990-02-07 EP disclosed
US-4703052-A Hypoglycemic thiazolidinediones PFIZER INC. (US) 1987-10-27 US disclosed
EP-0207605-A1 Hypoglycemic thiazolidinediones PFIZER INC. (US) 1987-01-07 EP disclosed
WO-1986007056-A1 HYPOGLYCEMIC THIAZOLIDINEDIONES PFIZER INC. (US) 1986-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119418-A1 BICYCLIC COMPOUND C1S, C1R, CYP11B2 ALDH1A1 2350/4885HPGD 2968/4885MAPT 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.